|
1.
|
Evens AM, Hong F. How can outcomes be improved for older patients with hodgkin lymphoma? J Clin Oncol. 2013 Apr 20; 31(12):1502-5.
|
|
|
|
|
2.
|
Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr; 161(1):76-86.
|
|
|
|
|
3.
|
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013 Jan 22; 110(4):1398-403.
|
|
|
|
|
4.
|
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012 Nov 11; 44(12):1321-5.
|
|
|
|
|
5.
|
Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M. Early Posttransplant Lymphoproliferative Disease: Clinicopathologic Features and Correlation With mTOR Signaling Pathway Activation. Am J Clin Pathol. 2012 Oct; 138(4):568-78.
|
|
|
|
|
6.
|
Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN. Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan in Patients with Relapsed/Refractory Follicular Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation. Leuk Lymphoma. 2012 Aug 20.
|
|
|
|
|
7.
|
Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol. 2012 Mar; 13(1):122-36.
|
|
|
|
|
8.
|
Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC. Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. Ann Oncol. 2012 Aug; 23(8):2128-37.
|
|
|
|
|
9.
|
Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012 Aug 1; 118(15):3743-8.
|
|
|
|
|
10.
|
Osborne CK, Evens A. Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. Oncology (Williston Park). 2011 Dec; 25(14):1422-4, 1426.
|
|
|
|
|
11.
|
Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012 Jan 19; 119(3):692-5.
|
|
|
|
|
12.
|
Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM. Analysis of very elderly (=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012 Jan; 156(2):196-204.
|
|
|
|
|
13.
|
Chen YH, Chadburn A, Evens AM, Winter JN, Gordon LI, Chenn A, Goolsby C, Peterson L. Clinical, Morphologic, Immunophenotypic, and Molecular Cytogenetic Assessment of CD4-/CD8- {gamma}{delta} T-Cell Large Granular Lymphocytic Leukemia. Am J Clin Pathol. 2011 Aug; 136(2):289-99.
|
|
|
|
|
14.
|
Chiu BC, Kwon S, Evens AM, Surawicz T, Smith SM, Weisenburger DD. Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma. Cancer Causes Control. 2011 Aug; 22(8):1183-95.
|
|
|
|
|
15.
|
Bhalla S, Evens AM, Dai B, Prachand S, Gordon LI, Gartenhaus RB. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood. 2011 Jul 28; 118(4):1052-61.
|
|
|
|
|
16.
|
Goddard A, Borovicka JH, West DP, Evens AM, Laumann A. Diffuse Large B-cell Lymphoma Associated With the Use of Biologic and Other Investigational Agents: The Importance of Long-term Post-marketing Safety Surveillance. J Drugs Dermatol. 2011 Jan; 10(1):80-3.
|
|
|
|
|
17.
|
Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011 May; 22(5):1170-80.
|
|
|
|
|
18.
|
Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep. 2010 Nov; 12(6):383-94.
|
|
|
|
|
19.
|
Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, Tung YT, Su YC. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor Fc?RIIIa 158(V/F) polymorphism. Am J Hematol. 2010 Oct; 85(10):810-2.
|
|
|
|
|
20.
|
Evens AM. Improving outcomes in PTLD. Oncology (Williston Park). 2010 Sep; 24(10):944, 946-7.
|
|
|
|
|
21.
|
Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K, Gordon LI. Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res. 2010 Oct 1; 16(19):4755-68.
|
|
|
|
|
22.
|
Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, Yan Au W, Srivastava G, Czader MB, Rizzieri DA, Lagoo AS, Lugar PL, Mann KP, Flowers CR, Bernal-Mizrachi L, Naresh KN, Evens AM, Gordon LI, Luftig M, Friedman DR, Weinberg JB, Thompson MA, Gill JI, Liu Q, How T, Grubor V, Gao Y, Patel A, Wu H, Zhu J, Blobe GC, Lipsky PE, Chadburn A, Dave SS. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 2010 Dec 2; 116(23):e118-27.
|
|
|
|
|
23.
|
Ahmed S, Winter JN, Gordon LI, Evens AM. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma. 2010 Jul; 51(7):1163-77.
|
|
|
|
|
24.
|
Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park). 2010 Jun; 24(7):574-87.
|
|
|
|
|
25.
|
Singh AT, Evens AM, Anderson RJ, Beckstead JA, Sankar N, Sassano A, Bhalla S, Yang S, Platanias LC, Forte TM, Ryan RO, Gordon LI. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):158-69.
|
|
|
|
|
26.
|
Bhalla S, Gordon LI, David K, Prachand S, Singh AT, Yang S, Winter JN, Guo D, O'Halloran T, Platanias LC, Evens AM. Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. Br J Haematol. 2010 Aug; 150(3):365-9.
|
|
|
|
|
27.
|
Singh AT, Evens AM, Prachand SN, Gordon LI. Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. Anticancer Res. 2010 Apr; 30(4):1131-6.
|
|
|
|
|
28.
|
Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010 Feb 20; 28(6):1038-46.
|
|
|
|
|
29.
|
O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Mac-Gregor Cortelli B, Blumel S, Evens AM, Zelenetz AD, Wright J, Cooper B, Winter J, Vose J. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010 Jan 15; 16(2):719-26.
|
|
|
|
|
30.
|
Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, Gascoyne RD, Gordon LI. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2010 Feb 20; 28(6):1017-24.
|
|
|
|
|
31.
|
Evens AM, Wagner LI. Curing Hodgkin's lymphoma: quantity and quality. Lancet Oncol. 2009 Dec; 10(12):1134-5.
|
|
|
|
|
32.
|
Evens AM, Spies WG, Helenowski IB, Patton D, Spies S, Jovanovic BD, Miyata S, Hamilton E, Variakojis D, Chen J, Naumovski L, Rosen ST, Winter JN, Miller RA, Gordon LI. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res. 2009 Oct 15; 15(20):6462-71.
|
|
|
|
|
33.
|
Mehta J, Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, Singhal S. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2009 Sep; 50(9):1434-41.
|
|
|
|
|
34.
|
Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009 May 15; 15(10):3354-65.
|
|
|
|
|
35.
|
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20):4834-40.
|
|
|
|
|
36.
|
Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W, Rademaker AW, Weitner BB, Williams SF, Tallman MS, Micallef I, Mehta J, Singhal S, Evens AM, Zimmer M, Molina A, White CA, Gordon LI. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2009 Apr 1; 27(10):1653-9.
|
|
|
|
|
37.
|
Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D. Primary mediastinal large B-cell lymphoma in HIV: report of two cases. J Hematop. 2009 Mar; 2(1):45-9.
|
|
|
|
|
38.
|
Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC. Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes Control. 2009 Jul; 20(5):517-23.
|
|
|
|
|
39.
|
Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park). 2008 Nov 15; 22(12):1369-79.
|
|
|
|
|
40.
|
Evens AM, Chiu BC. The challenges of epidemiologic research in non-Hodgkin lymphoma. JAMA. 2008 Nov 5; 300(17):2059-61.
|
|
|
|
|
41.
|
Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J, Evens A, Frankfurt O, Altman J, Gordon L, Tallman M, Williams S, Winter J, Singhal S, Mehta J. Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma? Bone Marrow Transplant. 2009 Feb; 43(4):301-5.
|
|
|
|
|
42.
|
Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008 Sep; 5(9):543-56.
|
|
|
|
|
43.
|
Kelemen K, Peterson LC, Helenowski I, Goolsby CL, Jovanovic B, Miyata S, Aranha O, Rosen ST, Winter JN, Nelson BP, Gordon LI, Evens AM. CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol. 2008 Aug; 130(2):166-77.
|
|
|
|
|
44.
|
Evens AM, Schumacker PT, Helenowski IB, Singh AT, Dokic D, Keswani A, Kordeluk E, Raji A, Winter JN, Jovanovic BD, Holmgren A, Nelson BP, Gordon LI. Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol. 2008 May; 141(5):676-80.
|
|
|
|
|
45.
|
Chiu BC, Dave BJ, Ward MH, Fought AJ, Hou L, Jain S, Gapstur S, Evens AM, Zahm SH, Blair A, Weisenburger DD. Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. Cancer Causes Control. 2008 Oct; 19(8):859-67.
|
|
|
|
|
46.
|
Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol. 2008 Feb; 140(4):385-93.
|
|
|
|
|
47.
|
David KA, Mauro L, Evens AM. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Curr Treat Options Oncol. 2007 Oct; 8(5):352-74.
|
|
|
|
|
48.
|
Soni LK, Hou L, Gapstur SM, Evens AM, Weisenburger DD, Chiu BC. Sun exposure and non-Hodgkin lymphoma: a population-based, case-control study. Eur J Cancer. 2007 Nov; 43(16):2388-95.
|
|
|
|
|
49.
|
Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J. Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma. 2007 Jul; 7(7):472-4.
|
|
|
|
|
50.
|
Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007 Sep; 40(5):451-6.
|
|
|
|
|
51.
|
Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug; 40(3):185-92.
|
|
|
|
|
52.
|
Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007 May 28; 167(10):1041-9.
|
|
|
|
|
53.
|
Chiu BC, Soni L, Gapstur SM, Fought AJ, Evens AM, Weisenburger DD. Obesity and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control. 2007 Aug; 18(6):677-85.
|
|
|
|
|
54.
|
Evens AM, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A, Miyata S, Catsaros K, Augustyniak C, Bennett CL, Tallman MS, Variakojis D, Winter JN, Gordon LI. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007 Jun; 137(6):545-52.
|
|
|
|
|
55.
|
Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007 Apr 15; 109(8):1532-5.
|
|
|
|
|
56.
|
Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007 Apr; 39(7):425-9.
|
|
|
|
|
57.
|
Evens AM, Altman JK, Mittal BB, Hou N, Rademaker A, Patton D, Kaminer L, Williams S, Duffey S, Variakojis D, Singhal S, Tallman MS, Mehta J, Winter JN, Gordon LI. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol. 2007 Apr; 18(4):679-88.
|
|
|
|
|
58.
|
Chen YH, Peterson LC, Dittmann D, Evens A, Rosen S, Khoong A, Shankey TV, Forman M, Gupta R, Goolsby CL. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol. 2007 Feb; 127(2):182-91.
|
|
|
|
|
59.
|
Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006 Dec 6; 296(21):2558-60.
|
|
|
|
|
60.
|
Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006 Dec; 135(5):642-50.
|
|
|
|
|
61.
|
McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5):599-604.
|
|
|
|
|
62.
|
Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol. 2006 Jul; 18(4):354-9.
|
|
|
|
|
63.
|
Mehta J, Gordon LI, Tallman MS, Winter JN, Evens AM, Evens AO, Frankfurt O, Williams SF, Grinblatt D, Kaminer L, Meagher R, Singhal S. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant. 2006 Jul; 38(2):95-100.
|
|
|
|
|
64.
|
Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, Fishman M, Masino K, Pi J, Mehta J. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006 Jun; 37(11):997-1001.
|
|
|
|
|
65.
|
Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AM, Evens AO, Frankfurt O, Williams SF, Grinblatt D, Kaminer L, Meagher R, Mehta J. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 Mar; 37(6):553-7.
|
|
|
|
|
66.
|
Evens AM, Querfeld C, Rosen ST. T-cell non-Hogdkin's lymphoma. Cancer Treat Res. 2006; 131:161-220.
|
|
|
|
|
67.
|
Engel RH, Evens AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci. 2006; 11:300-12.
|
|
|
|
|
68.
|
Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood. 2006 Feb 15; 107(4):1255-64.
|
|
|
|
|
69.
|
Tomblyn M, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Evens A, Mehta J. Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF. Bone Marrow Transplant. 2005 Oct; 36(8):663-6.
|
|
|
|
|
70.
|
Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15; 106(10):3343-7.
|
|
|
|
|
71.
|
Evens AM, Balasubramanian L, Gordon LI. Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. Curr Treat Options Oncol. 2005 Jul; 6(4):289-96.
|
|
|
|
|
72.
|
Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, Evens AM, Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005 May 4; 293(17):2131-40.
|
|
|
|
|
73.
|
Gidron A, Verma A, Doyle M, Boggio L, Evens A, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? Bone Marrow Transplant. 2005 Feb; 35(3):243-6.
|
|
|
|
|
74.
|
Carson KR, Evens AM, Bennett CL, Luminari S. Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005; 18(3):467-72.
|
|
|
|
|
75.
|
Evens AM, Bennett CL, Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol. 2005; 18(3):481-9.
|
|
|
|
|
76.
|
Evens AM. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol. 2004 Nov; 16(6):576-80.
|
|
|
|
|
77.
|
Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant. 2004 Oct; 34(7):561-71.
|
|
|
|
|
78.
|
Evens AM, Gordon LI. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. Clin Lymphoma. 2004 Oct; 5 Suppl 1:S11-5.
|
|
|
|
|
79.
|
Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004 Sep 30; 351(14):1403-8.
|
|
|
|
|
80.
|
Evens AM, Lecane P, Magda D, Prachand S, Singhal S, Nelson J, Miller RA, Gartenhaus RB, Gordon LI. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood. 2005 Feb 1; 105(3):1265-73.
|
|
|
|
|
81.
|
Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res. 2004 Sep; 28(9):891-900.
|
|
|
|
|
82.
|
Evens AM, Gartenhaus RB. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol. 2004 Aug; 5(4):289-303.
|
|
|
|
|
83.
|
Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB. Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res. 2004 Feb 15; 10(4):1481-91.
|
|
|
|
|
84.
|
Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood. 2003 Jul 1; 102(1):297-302.
|
|
|
|
|
85.
|
Evens AM, Gartenhaus RB. Molecular etiology of mature T-cell non-Hodgkin's lymphomas. Front Biosci. 2003 Jan 1; 8:d156-75.
|
|
|
|
|
86.
|
Evens AM, Kwaan HC, Kaufman DB, Bennett CL. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation. 2002 Sep 27; 74(6):885-7.
|
|
|
|
|
87.
|
Evens AM, Gordon LI. Burkitt's and Burkitt-like lymphoma. Curr Treat Options Oncol. 2002 Aug; 3(4):291-305.
|
|
|
|
|
88.
|
Evens AM, Lestingi TM, Bitran JD. Intermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review. Oncologist. 1998; 3(6):419-423.
|
|
|
|
